Evidence of treatment benefit: Is seeing believing or obfuscation by statistics?

Multiple Sclerosis

Volumn 15, Issue 11, 2009, Pages 1251-1252

  Cutter, Gary ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLATIRAMER; INTERFERON;

CLINICAL PRACTICE; COST EFFECTIVENESS ANALYSIS; EDITORIAL; EVIDENCE BASED MEDICINE; EXPANDED DISABILITY STATUS SCALE; HAZARD RATIO; MULTIPLE SCLEROSIS; OBSERVATIONAL STUDY; RISK REDUCTION; STATISTICS;

DATA INTERPRETATION, STATISTICAL; DISABILITY EVALUATION; FOLLOW-UP STUDIES; HUMANS; MULTIPLE SCLEROSIS; RESEARCH DESIGN; TREATMENT OUTCOME;

EID: 70450191765     PISSN: 13524585     EISSN: None     Source Type: Journal    
DOI: 10.1177/1352458509350169     Document Type: Editorial

References (2)

1. Veugelers PJ, Fisk JD, Brown MG, et al. Disease progression among multiple sclerosis patients before and during a disease-modifying drug program: A longitudinal population-based evaluation. Mult Scler 2009; 15: 1286-1294.
2. Weinshenker BG, Bass B., Rice GPA, et al. The natural history of multiple sclerosis: A geographically based study. Brain 1991; 114: 1057-1067.